Phase 2 vs Phase 3 — Rare Disease Deal Valuation Comparison

Phase 2 deals are more milestone-weighted (82% milestones), reflecting higher clinical risk. Phase 3 deals shift toward higher upfront allocations (29% upfront) as clinical de-risking reduces the need for contingent milestone structures.

The optimal licensing window depends on strategic priorities. Phase 2 assets offer lower entry cost for licensees, while Phase 3 assets provide more certainty. The 114% premium from Phase 2 to Phase 3 reflects the value created by clinical data, making the transition point critical for deal timing.